Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 228 Other hematologic neoplasm 214 Plasma cell 92 Myeloid 85 Sarcoma 68 CNS 56 Breast 52 Genitourinary 37 Gynecologic 33 Classical hematology 30 Dermatologic 21 Other solid neoplasm 20 Thoracic 13 Gastrointestinal 13 Head & Neck 12 Endocrine 3 Other neoplasm 2 NET 2 Tumor-Agnostic 1 Other 1

Conditions

Interventions

Surveys and Questionnaires 70 Blood Specimen Collection 48 Radiotherapy 39 Magnetic Resonance Spectroscopy 35 pembrolizumab 31 Gemcitabine 30 Bevacizumab 30 Nivolumab 29 Carboplatin 29 Radiosurgery 27 Standard of Care 26 Oxaliplatin 26 Capecitabine 25 Paclitaxel 24 Interviews as Topic 24 Cisplatin 24 Fluorouracil 23 Erlotinib Hydrochloride 22 Everolimus 19 Irinotecan 18 Trastuzumab 17 Methods 17 Exercise 17 Docetaxel 17 Biopsy 17 Cyclophosphamide 16 Educational Status 15 Sorafenib 14 Ipilimumab 14 Fluorodeoxyglucose F18 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Filgrastim × Tumor-Agnostic × Clear all

NCT01057264 2015-11-18

HAI Abraxane With Gemcitabine and Bevacizumab

M.D. Anderson Cancer Center

Phase 1 Completed

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡